| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA506: Lesinurad for treating chronic hyperuricaemia in people with gout |
|
Medicine details |
|
| Medicine name | lesinurad (Zurampic®) |
| Formulation | 200 mg film-coated tablet |
| Reference number | 1477 |
| Indication | In combination with a xanthine oxidase inhibitor for the adjunctive treatment of hyperuricaemia in adult gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/03/2016 |
| NICE guidance | TA506: Lesinurad for treating chronic hyperuricaemia in people with gout |